Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenqi Sherong Pill is a Traditional Chinese Medicine (TCM) candidate developed by Shanghai Hutchison Pharmaceuticals for the treatment of mild to moderate cervical spondylotic myelopathy (CSM). It is specifically formulated for patients presenting with the TCM syndrome of Qi deficiency, blood stasis, and kidney deficiency (气虚血瘀肾亏证). The drug is currently undergoing Phase III clinical evaluation in China to assess its efficacy and safety compared to placebo, with the goal of supporting a New Drug Application (NDA). As a TCM formulation, it likely contains multiple botanical and animal-derived ingredients intended to improve microcirculation and support neurological function in the context of spinal cord compression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shenqi Sherong Pill.